Enorama Pharma: BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING OF ENORAMA PHARMA AB (PUBL)
Idag, 14:45
Enorama Pharma: BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING OF ENORAMA PHARMA AB (PUBL)
On 20 March 2026 an extraordinary general meeting was held in Enorama Pharma AB (publ), reg. no. 556716-5591 ("Enorama Pharma" or the "Company"). Below is a summary of the adopted resolutions.
Resolution on approval of related party transactions regarding extending loan agreement
The general meeting resolved, in accordance with the board of directors’ proposal, to extend the maturity date of the loan agreement entered into by Enorama Pharma on 18 May 2022 with the major shareholder DS Global Pte. Limited ("DS Global"), regarding a loan of SEK twenty million (20,000,000) (the "Existing Loan Agreement"). The Existing Loan Agreement was extended from 28 February 2026 to 31 December 2027.
Resolution onapproval of related party transactions regarding entering into loan agreement
The general meeting resolved, in accordance with the board of directors’ proposal, to approve the loan agreement entered into by Enorama Pharma on 18 February 2026 with DS Global, which was subject to subsequent approval by the general meeting (the "New Loan Agreement"). Through the New Loan Agreement, DS Global is making available a loan facility of USD 4 million (4,000,000) to Enorama Pharma.
Further information about the loan agreements can be found in the press release published by the Company on 18 February 2026, the notice of the general meeting published on 3 March 2026, and the board of directors' report pursuant to the Swedish Securities Council's statement 2019:25. Shares and votes held directly or indirectly by DS Global or other companies under the same control were not taken into account in the resolutions.
CONTACT
Enorama Pharma AB (publ)
Bengt Jönsson, acting CEO
info@enorama.se
Strandvägen 7A, 114 51 Stockholm
www.enorama.se
Enorama Pharma AB is listed on Nasdaq First North Growth Market.
The Company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, ca@tapperpartners.se.
ABOUT ENORAMA PHARMA
Enorama Pharma's vision is to be a leading global producer and supplier of consumer-friendly, oral nicotine products. The Company intends to expand through product and brand development and by establishing strategically important collaborations. For more information, visit www.enorama.se.
Ämnen i artikeln
Enorama Pharma: BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING OF ENORAMA PHARMA AB (PUBL)
Idag, 14:45
Enorama Pharma: BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING OF ENORAMA PHARMA AB (PUBL)
On 20 March 2026 an extraordinary general meeting was held in Enorama Pharma AB (publ), reg. no. 556716-5591 ("Enorama Pharma" or the "Company"). Below is a summary of the adopted resolutions.
Resolution on approval of related party transactions regarding extending loan agreement
The general meeting resolved, in accordance with the board of directors’ proposal, to extend the maturity date of the loan agreement entered into by Enorama Pharma on 18 May 2022 with the major shareholder DS Global Pte. Limited ("DS Global"), regarding a loan of SEK twenty million (20,000,000) (the "Existing Loan Agreement"). The Existing Loan Agreement was extended from 28 February 2026 to 31 December 2027.
Resolution onapproval of related party transactions regarding entering into loan agreement
The general meeting resolved, in accordance with the board of directors’ proposal, to approve the loan agreement entered into by Enorama Pharma on 18 February 2026 with DS Global, which was subject to subsequent approval by the general meeting (the "New Loan Agreement"). Through the New Loan Agreement, DS Global is making available a loan facility of USD 4 million (4,000,000) to Enorama Pharma.
Further information about the loan agreements can be found in the press release published by the Company on 18 February 2026, the notice of the general meeting published on 3 March 2026, and the board of directors' report pursuant to the Swedish Securities Council's statement 2019:25. Shares and votes held directly or indirectly by DS Global or other companies under the same control were not taken into account in the resolutions.
CONTACT
Enorama Pharma AB (publ)
Bengt Jönsson, acting CEO
info@enorama.se
Strandvägen 7A, 114 51 Stockholm
www.enorama.se
Enorama Pharma AB is listed on Nasdaq First North Growth Market.
The Company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, ca@tapperpartners.se.
ABOUT ENORAMA PHARMA
Enorama Pharma's vision is to be a leading global producer and supplier of consumer-friendly, oral nicotine products. The Company intends to expand through product and brand development and by establishing strategically important collaborations. For more information, visit www.enorama.se.
Ämnen i artikeln
Oljepriset
Analys
Semester
Aktieråd
Styrräntan
Oljepriset
Analys
Semester
Aktieråd
Styrräntan
Marknadsöversikt
1 DAG %
Senast
1 mån
